| MeSH term | MeSH ID | Detail |
|---|---|---|
| Inflammatory Bowel Diseases | D015212 | 9 associated lipids |
| Reperfusion Injury | D015427 | 65 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Fatty Liver | D005234 | 48 associated lipids |
| Cataract | D002386 | 34 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sheiner PA et al. | Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. | 1994 | Transplantation | pmid:7513099 |
| Therapondos G et al. | Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? | 2003 | Transplantation | pmid:12883220 |
| Burroughs TE et al. | Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. | 2007 | Transplantation | pmid:17452891 |
| Andrades KM et al. | Modulation of Candida albicans virulence by antirejection immunosuppressant drugs. | 2013 | Transplantation | pmid:23380869 |
| Adams PS et al. | Postoperative cardiac tamponade after kidney transplantation: a possible consequence of alemtuzumab-induced cytokine release syndrome. | 2013 | Transplantation | pmid:23380870 |
| Migita K et al. | FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. | 1999 | Transplantation | pmid:10532544 |
| Boleslawski E et al. | Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. | 2004 | Transplantation | pmid:15223897 |
| Hostettler KE et al. | Cyclosporine A mediates fibroproliferation through epithelial cells. | 2004 | Transplantation | pmid:15223908 |
| Yang CW et al. | Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. | 2003 | Transplantation | pmid:12544865 |
| Bilolo KK et al. | Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. | 2003 | Transplantation | pmid:12811249 |
| Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
| Morrissey PE et al. | Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. | 1997 | Transplantation | pmid:9089224 |
| Kiuchi T et al. | A hepatic graft tuberculosis transmitted from a living-related donor. | 1997 | Transplantation | pmid:9089234 |
| Gerlach UA et al. | Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. | 2017 | Transplantation | pmid:27607529 |
| Karlsson H and Nässberger L | FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. | 1997 | Transplantation | pmid:9355847 |
| Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
| Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
| Thervet E et al. | Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. | 2003 | Transplantation | pmid:14578760 |
| Burroughs TE et al. | Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. | 2009 | Transplantation | pmid:19667939 |
| Mittal SK et al. | Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. | 2009 | Transplantation | pmid:19667950 |
| Nobori S et al. | Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. | 2006 | Transplantation | pmid:16421473 |
| Kung L and Halloran PF | Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. | 2000 | Transplantation | pmid:10933159 |
| Beatty PR et al. | Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. | 1998 | Transplantation | pmid:9603175 |
| Maes BD et al. | Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. | 1999 | Transplantation | pmid:10589943 |
| Gruber SA et al. | Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. | 2000 | Transplantation | pmid:10933170 |
| Shapiro R et al. | Alopecia as a consequence of tacrolimus therapy. | 1998 | Transplantation | pmid:9603186 |
| Fernandez LA et al. | The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. | 1999 | Transplantation | pmid:10589951 |
| Mehra MR et al. | Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. | 2002 | Transplantation | pmid:12490790 |
| Gruessner RW and Sharp HL | Living-related intestinal transplantation: first report of a standardized surgical technique. | 1997 | Transplantation | pmid:9415566 |
| Swinnen LJ et al. | Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. | 2008 | Transplantation | pmid:18645482 |
| Shapiro R et al. | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. | 2008 | Transplantation | pmid:18431232 |
| Welberry Smith MP and Baker RJ | The author's reply. | 2014 | Transplantation | pmid:24978039 |
| Singla AK et al. | Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. | 2014 | Transplantation | pmid:24949498 |
| Walsh C et al. | Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients. | 2013 | Transplantation | pmid:23296149 |
| de Fijter JW | Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? | 2011 | Transplantation | pmid:21654351 |
| Brunet M et al. | Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. | 2006 | Transplantation | pmid:16495801 |
| Taylor-Fishwick DA et al. | Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. | 1993 | Transplantation | pmid:7689258 |
| Borni-Duval C et al. | Risk factors for BK virus infection in the era of therapeutic drug monitoring. | 2013 | Transplantation | pmid:23778568 |
| van Boekel GA et al. | Effect of mild diarrhea on tacrolimus exposure. | 2012 | Transplantation | pmid:22955188 |
| Mourer JS et al. | Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. | 2012 | Transplantation | pmid:22955227 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. | 2004 | Transplantation | pmid:14742990 |
| Azzola A et al. | Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. | 2004 | Transplantation | pmid:14742993 |
| Wang X et al. | Immunosuppression with a combination of pg490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. | 2005 | Transplantation | pmid:15940043 |
| Nankivell BJ et al. | Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. | 2004 | Transplantation | pmid:15167607 |
| Warty V et al. | FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. | 1988 | Transplantation | pmid:2458643 |
| Kuypers DR et al. | Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. | 2006 | Transplantation | pmid:16794545 |
| Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
| Uemoto S et al. | Experience with FK506 in living-related liver transplantation. | 1993 | Transplantation | pmid:7679528 |
| Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |